Amyotrophic Lateral Sclerosis Lou Gehrig's Disease
Conditions
Interventions
Participants will be randomized in a 2:1 ratio to the SAR443820 treatment arm
or matching placebo arm as listed below:
• Treatment arm: SAR443820, 20 mg, BID
• Placebo arm: Placebo, BID
Sponsors
Sanofi BV
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Male or female, 18-80 years of age (inclusive) • Diagnosis of possible, clinically probable ALS, clinically probable laboratory-supported ALS, or clinically definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria • Time since onset of first symptom of ALS =60% of the predicted value. • Be able to swallow the study tablets at the screening visit. • Either not currently receiving riluzole or on a stable dose of riluzole for at least 4 weeks before the screening visit. Participants receiving riluzole are expected to remain on the same dose throughout the duration of the study. • Either not currently receiving edaravone or on the approved standard schedule of edaravone treatment. Participants receiving edaravone must have completed at least 1 cycle of treatment before the screening visit and are expected to continue edaravone treatment throughout the duration of the study. • Weight : Participants with a body weight no less than 45 kg and body mass index no less than 18 kg/m2. • Female participants with childbearing potential are eligible to participate if they are not pregnant or breastfeeding and agree to use adequate contraceptive method during study intervention period and for at least 32 days after the last dose of study drug. • Male participants must agree to use highly effective contraceptive method during the study period and for at least 92 days following their last dose of the study drug. Male participants must not donate sperms for the duration of study and 92 days after last dose of study drug.
Exclusion criteria
Exclusion criteria: • A history of seizure (History of febrile seizure during childhood is allowed). • Having central IV lines, such as a peripherally inserted central catheter (PICC) or midline or port-a-cath lines. • With significant cognitive impairment, psychiatric disease, other neurodegenerative disorder (eg, Parkinson disease or AD), substance abuse, or any other condition that would make the participants unsuitable for participating in the study or could interfere with assessment or completing the study in the opinion of the Investigator. • History of recent serious infection (eg, pneumonia, septicemia) within 4 weeks of the screening visit; infection requiring hospitalization or treatment with IV antibiotics, antivirals, or antifungals within 4 weeks of screening; or chronic bacterial infection (such as tuberculosis) deemed unacceptable as per the Investigator's judgment. • With active herpes zoster infection within 2 months prior to the screening visit. • A documented history of attempted suicide within 6 months prior to the screening visit, present with suicidal ideation of category 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS), or in the Investigator's judgment are at risk for a suicide attempt. • History of unstable or severe cardiac, pulmonary, oncological, hepatic, or renal disease or another medically significant illness other than ALS precluding their safe participation in this study. • Participants who are pregnant or are currently breastfeeding. • A known history of allergy to any ingredients of SAR443820. Prior/concomitant therapy : • Currently or previously treated with any strong or moderate CYP3A4 inhibitors or strong CYP3A4 inducers listed in Appendix 10 of the protocol within the specified washout period before the screening visit. • Received a live vaccine within 14 days before the screening visit. • Participants with concurrent participation in any other interventional clinical study or who have received treatment with another investigational drug within 4 weeks or 5 half-lives of the investigational agent before the screening visit, whichever is longer. • Participants who have received stem cell or gene therapy for ALS at any time in the past. • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3.0 × upper limit of normal (ULN) • Bilirubin >1.5 × ULN unless the participant has documented Gilbert syndrome (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part A: Change from baseline in the ALSFRS-R total score from screening to Week 24 Part B: Combined assessment of the function and survival (CAFS) score at Week 52 | — |
Secondary
| Measure | Time frame |
|---|---|
| Part A: - Combined assessment of the function and survival (CAFS) score at Week 24 - Change from baseline in slow vital capacity (SVC) to Week 24 - Muscle strength measured by handheld dynamometry (HHD) over 24 weeks - Change from baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5) to Week 24 - Change from baseline in serum neurofilament light chain (NfL) to Week 24 - Incidence of adverse events (AE), serious adverse events (SAE), treatment-emergent adverse events (TEAE), potentially clinically significant abnormalities (PCSA) in laboratory tests, electrocardiogram (ECG), and vital signs over 24 weeks - Plasma concentration of SAR443820 Part B: - Combined assessment of the function and survival (CAFS) score at Week 76 and Week 104 - Change from baseline in the ALSFRS-R total score to Week 52, Week 76, and Week 104 - Time from baseline to the occurrence of either death or permanent assisted ventilation (>22 hours daily for >7 consecutive days), whichever comes first, before Week 52, Week 76, and Week 104 - Time from baseline to the occurrence of death before Week 52, Week 76, and Week 104 - Change from baseline in slow vital capacity (SVC) to Week 52, Week 76, and Week 104 - Change from baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5) to Week 52, Week 76, and Week 104 - Change from baseline in serum neurofilament light chain (NfL) to Week 52 - Incidence of adverse events (AE), serious adverse events (SAE), treatment-emergent adverse events (TEAE), potentially clinically significant abnormalities (PCSA) in laboratory tests, electrocardiogram (ECG), and vital signs during Part B - Plasma concentration of SAR443820 | — |
Countries
Netherlands
Outcome results
None listed